Similarly, the utilization of CAR-modified peripheral blood lymphocytes, known as CARMA-hMeso, for the targeting of HER2/neu-positive OC cells has shown advantages in restraining tumor growth and enhancing survival rates in mouse models (73). Here, ERBB2 is linked to neoplasm.